Sun Pharmaceutical Industries Ltd
Sun Pharma: CRISIL, ICRA Assign/Reaffirm Top Ratings; NCD Programme Rated
RATING
▲ Positive Development
LOW RISK
📅 Filed on BSE: 13 Oct 2026, 05:53 PM IST · BSE ID: f039d44f-8dbf-42dd-bf8b-d2a9e290ecb6
View Original BSE Filing (PDF)
💡
In Simple Terms
Credit rating agencies reaffirmed Sun Pharma's highest scores, indicating strong financial health for its debt plans.
🤖 AI Summary
- CRISIL and ICRA assigned top 'AAA/Stable' ratings to Sun Pharma's proposed NCD programme.
- Existing long-term and short-term ratings were reaffirmed at 'AAA/Stable' and 'A1+' respectively.
- Ratings consider Sun Pharma's strong business and financial profile and proposed Organon & Co. acquisition.
- Sun Pharma Laboratories Limited's INR 150 crore facilities reaffirmed at '[ICRA]A1+'.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Proposed NCD Programme Rating (CRISIL)
Crisil AAA/Stable
Proposed NCD Programme Rating (ICRA)
[ICRA]AAA (Stable)
Existing Long Term Rating (CRISIL)
Crisil AAA/Stable
Existing Short Term Rating (CRISIL)
Crisil A1+
Existing Long-term short-term, fund-based/ non-fund-based limits Rating (ICRA)
[ICRA]AAA (Stable)/ [ICRA]A1+
Sun Pharma Laboratories Limited Facilities Rating (ICRA)
[ICRA]A1+
Sun Pharma Laboratories Limited Facilities Aggregate Value
INR 150 crore
🏢 How This Affects the Company
Top credit ratings enhance the company's ability to raise debt capital at favourable terms for strategic initiatives, including potential acquisitions.
The reaffirmed high ratings support Sun Pharma's financial flexibility and stability, facilitating access to debt markets with reduced borrowing costs.
Strong credit ratings generally indicate a lower perceived risk by rating agencies, reflecting confidence in the company's financial management.
👥 What This Means For Shareholders
✅
Action Required
No action is required by shareholders. This is a credit rating update concerning the company's debt instruments.
👤
Who Is Affected
Existing and potential debenture holders are affected by the reaffirmed high credit quality, indicating lower risk for debt investments.
🔍
Management Signal
Management continues to maintain and signal a strong financial discipline and strategic focus, reflected in the top credit ratings.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Disclosure of terms for the proposed NCD programme.
Updates on the proposed acquisition of Organon & Co.
Future credit rating reviews by CRISIL and ICRA.
LOW RISK
Credit rating updates affirm company's financial stability and strong market position.
💡 Investor Takeaway
Sun Pharma's proposed Non-Convertible Debenture programme and existing facilities have been assigned or reaffirmed with the highest credit ratings ('AAA/Stable') by CRISIL and ICRA.
⚖️ Strengths & Concerns
✅ Positives
- CRISIL and ICRA assigned 'Crisil AAA/Stable' and '[ICRA]AAA (Stable)' respectively to Sun Pharma's proposed NCD programme.
- Existing long-term ratings reaffirmed at 'Crisil AAA/Stable' and '[ICRA]AAA (Stable)' by both agencies.
📅 Company Track Record
In August 2026, Sun Pharma's long-term credit rating was reaffirmed at CRISIL AAA/Stable by CRISIL, indicating a consistent track record of strong creditworthiness.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What credit ratings has CRISIL assigned to Sun Pharmaceutical Industries Limited?
CRISIL has assigned 'Crisil AAA/Stable' to the proposed Non-Convertible Debentures and reaffirmed 'Crisil AAA/Stable/Crisil A1+' on existing facilities.
What credit ratings has ICRA assigned to Sun Pharmaceutical Industries Limited?
ICRA has assigned '[ICRA]AAA (Stable)' to the proposed Non-Convertible Debentures and reaffirmed '[ICRA]AAA (Stable)/ [ICRA]A1+' on existing limits.
What is the rating for Sun Pharma Laboratories Limited's facilities?
ICRA has reaffirmed the rating of '[ICRA]A1+' to the short-term facilities of Sun Pharma Laboratories Limited, aggregating INR 150 crore.
What factors are considered in Sun Pharma's credit ratings?
The ratings consider the company's strong business and financial profile, and the proposed acquisition of Organon & Co.
Questions based on this BSE filing only. For information purposes.